Successful therapy of refractory erythema nodosum associated with Crohn’s disease using potassium iodide

John K Marshall MD FRCPC, E Jan Irvine MD MSc FRCPC

Erythema nodosum (EN) is the most common dermatological manifestation of inflammatory bowel disease (IBD). It arises in 10% to 15% of IBD patients and is associated more frequently with Crohn’s disease than with ulcerative colitis (1). We report successful therapy of severe, refractory erythema nodosum associated with Crohn’s colitis using oral potassium iodide. While the mechanism of action of this agent is poorly understood, it appears to be an effective and nontoxic therapy for Crohn’s-related erythema nodosum and warrants further evaluation in a placebo controlled trial.

Key Words: Crohn’s disease, Erythema nodosum, Potassium iodide

JK Marshall, EJ Irvine. Successful therapy of refractory erythema nodosum associated with Crohn’s disease using potassium iodide. Can J Gastroenterol 1997;11(6):501-502. Erythema nodosum is a common extraintestinal manifestation of Crohn’s disease. While mild skin involvement often responds to conservative management, severe or refractory cases may require systemic corticosteroid or immunosuppressive therapy. This report describes successful treatment of severe, refractory erythema nodosum associated with Crohn’s colitis using oral potassium iodide. While the mechanism of action of this agent is poorly understood, it appears to be an effective and nontoxic therapy for Crohn’s-related erythema nodosum and warrants further evaluation in a placebo controlled trial.

Réussite du traitement de l’érythème noueux réfractaire associé à la maladie de Crohn à l’aide d’iodure de potassium

RÉSUMÉ : L’érythème noueux est une manifestation extra-intestinale courante de la maladie de Crohn. Si l’atteinte cutanée légère répond souvent au traitement classique, les cas graves ou réfractaires peuvent nécessiter l’administration de corticothérapie et de traitements immuno-suppressifs systémiques. Ce rapport décrit la réussite du traitement d’un érythème noueux, grave et réfractaire, associé à la colite de Crohn à l’aide d’iodure de potassium. Si le mode d’action de cet agent est mal compris, il semble agir sans toxicité dans les cas d’érythème noueux associé à la maladie de Crohn et il gagnerait à faire l’objet d’un essai contrôlé par placebo.

Can J Gastroenterol Vol 11 No 6 September 1997
aphthous ulceration. Oral prednisone 40 mg/day was prescribed but without effect. Over the following four months, the EN became more extensive and increasingly painful. Oral cyclosporine 300 mg/day was added to her treatment. Despite four weeks of therapy, the EN continued to worsen so the cyclosporine was tapered off. Treatment was then initiated with a saturated solution of potassium iodide at a dose of 30 drops/day (approximately 1500 mg).

The EN improved dramatically within two weeks and healed completely by four months, when the potassium iodide was discontinued. Twelve months later, the EN recurred and, again, it responded rapidly to a four-week course of oral potassium iodide. Four months later, the patient’s colitis remains in clinical remission, and she has suffered no further recurrence of EN.

**DISCUSSION**

EN, which occurs in 10% to 15% of patients with IBD, is more common in patients with Crohn’s disease and colonic involvement (1). Patients present with tender, red subcutaneous nodules of the lower extremities. Although the etiology of EN is unclear, biopsy typically reveals histological evidence of a septal panniculitis. While the severity of EN tends to reflect the activity of the underlying colitis, it may also occur in association with clinically quiescent disease, as was the case in our patient.

Mild EN can be treated successfully with bedrest and analgesia, along with the administration of salicylates or nonsteroidal anti-inflammatory agents. We decided to avoid these medications in our patient because of the risk of Crohn’s disease exacerbation associated with their use. Although EN associated with underlying IBD usually responds to medical or surgical management of the colitis, our patient had active EN despite clinical and endoscopic remission of her Crohn’s disease. Refractory or severe EN may respond to systemic corticosteroids, hydroxychloroquine or cyclosporine, but these agents often give unsatisfactory results and may also be associated with serious systemic toxicity.

Potassium iodide, although widely used for dermatological disorders in the early part of this century (2), has never been tested rigorously in a placebo controlled trial. Authors of uncontrolled reports have proposed oral iodides as treatment for nodular vasculitis (3-5), erythema multiforme (4), Sweet’s syndrome (6), cutaneous sporotrichosis (7), pulmonary aspergillosis (8) and pyoderma gangrenosum (9). The first large case series of patients treated for EN was reported by Schulz and Whiting in 1976 (3). A favourable response was observed in 24 of 28 patients given potassium iodide at a dose of 360 to 900 mg/day. Improvement occurred at two days with complete resolution at two weeks. Horio et al (5) later treated 15 patients with EN using oral potassium iodide 900 mg/day (5). Eleven of 15 patients responded dramatically within a few days and were healed completely by two weeks. No clinical characteristics at presentation were found to predict response. In another series, Heid et al (10) noted a rapid response in five patients with EN who were administered potassium iodide 1000 mg/day. In each of these case series, no drug-related adverse effects were reported. Of interest, ours is the first reported case of successful potassium iodide therapy in which EN was associated with underlying IBD.

It is not known why EN responds to potassium iodide therapy. The suppression of oxygen-free radical formation (11), inhibition of leukocyte chemotaxis (12) or release of heparin from mast cell granules (13) have been hypothesized to be the putative mechanism of action. While published case series report potassium iodide to be well tolerated, iodides have been associated with dose-related adverse effects such as nausea, a metallic taste, corzya, bronchorrhea, sialoadenitis, thyrotoxicosis and ‘cutaneous iodine’, a pustular acniform eruption (14). Hypersensitivity reactions characterized by fever, arthralgia, asthma or eosinophilia are also described (14). Indeed, potassium iodide has been reported, paradoxically, to cause EN in some patients (15). Our patient suffered no adverse events attributable to the drug despite two courses of therapy at a relatively high dose over five months.

**CONCLUSIONS**

Potassium iodide shows promise as an inexpensive and relatively nontoxic therapy for patients with refractory erythema nodosum complicating IBD. Placebo controlled trials are needed to confirm its efficacy and to define more accurately its adverse effects in this population.

**REFERENCES**
